9.37
+0.11%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Pelthos Therapeutics
From its filings with the US Securities and Exchange Commission
Pelthos Therapeutics is based in Durham, North Carolina and is incorporated in Nevada. Its shares trade on NYSE under the ticker PTHS. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $16.8m and a net loss of $43.3m. At that date it held total assets of $130.4m and shareholders' equity of $38.9m.
Pelthos Therapeutics Inc. (the “Company”) is a bio-pharmaceutical company committed to commercializing innovative, safe, and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S. Food and Drug Administration (“FDA”) approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMITM, XEPI®, and XEGLYZE®.
The July 1, 2025 merger transaction between Channel Therapeutics Corporation (“Channel”) and LNHC, Inc. (“LNHC”), discussed below, resulted in Pelthos Therapeutics Inc. initially having (i) a commercially marketable product, ZELSUVMI for the treatment of molluscum contagiosum, which was launched in July 2025 shortly after the Merger (as defined below); (ii) a manufacturing facility, equipment and know-how to produce the active pharmaceutical ingredient (“API”) used in ZELSUVMI and the NITRICILTM technology platform; and (iii) clinical-stage assets which selectively target the sodium ion-channel known as “NaV1.7”, which has been genetically validated as a pain receptor in human physiology. In addition, during the fourth quarter of 2025 the Company acquired two additional FDA approved products to expand its commercial product portfolio.
Quoted from its 10-K, filed 19 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 16 Feb 2024
- Employees
- 4
- Website
- ir.pelthos.com ↗
- Head office
- 4020 STIRRUP CREEK DRIVE, DURHAM, NC, 27703
- Incorporated in
- NV
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Mr. Peter GreenleafChairman of the Board
- Mr. Scott PleshaPresident, Chief Executive Officer, Director, since 2025
- Mr. Francis KnuettelChief Financial Officer, Treasurer, Company Secretary$843,422
- Mr. Sai RangaraoChief Commercial Officer
- Mr. Andrew EinhornDirector
- Mr. Richard BaxterIndependent Director
- Mr. Todd DavisIndependent Director$385,869
- Mr. Ezra FriedbergIndependent Director$210,115
- Dr. Richard MalamutIndependent Director$210,115
- Mr. Matthew PaulsIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Lead product ZELSUVMI is an FDA-designated novel drug for molluscum treatment
- Pelthos Therapeutics has a small team of 4 employees focused on biotechnology
- The company's lead product ZELSUVMI is approved for home use by parents and caregivers
Weaknesses
- The company has only 4 employees which may limit operational capacity
- Pelthos Therapeutics has no other products besides ZELSUVMI in development
- The firm's NaV 1.7 development programs are still in evaluation phase
Opportunities
- The FDA-approved ZELSUVMI can be marketed to adults and pediatric patients in the US
- Pelthos Therapeutics can expand its NaV 1.7 programs for chronic pain treatments
- The company can leverage its FDA designation for future drug approvals
Threats
- The small team of 4 employees may hinder rapid market expansion
- Pelthos Therapeutics faces competition from other biotechnology firms in the US
- The NaV 1.7 development programs could face regulatory delays
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.